WO2004059293A3 - Markers for differential diagnosis and methods of use thereof - Google Patents
Markers for differential diagnosis and methods of use thereof Download PDFInfo
- Publication number
- WO2004059293A3 WO2004059293A3 PCT/US2003/041453 US0341453W WO2004059293A3 WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3 US 0341453 W US0341453 W US 0341453W WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- differential diagnosis
- markers
- diseases
- compositions
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002511501A CA2511501A1 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
AU2003302340A AU2003302340B8 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
EP03810896A EP1587955A4 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
JP2005510072A JP2006526140A (en) | 2002-12-24 | 2003-12-23 | Marker for differential diagnosis and method of using the same |
IL169348A IL169348A0 (en) | 2002-12-24 | 2005-06-23 | Markers for differential diagnosis and methods of use thereof |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43630102P | 2002-12-24 | 2002-12-24 | |
US60/436,301 | 2002-12-24 | ||
US10/330,696 | 2002-12-27 | ||
US10/330,696 US7713705B2 (en) | 2002-12-24 | 2002-12-27 | Markers for differential diagnosis and methods of use thereof |
US10/371,149 | 2003-02-20 | ||
US10/371,149 US20030199000A1 (en) | 2001-08-20 | 2003-02-20 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/603,891 | 2003-06-24 | ||
US10/603,891 US20040253637A1 (en) | 2001-04-13 | 2003-06-24 | Markers for differential diagnosis and methods of use thereof |
US10/673,077 | 2003-09-26 | ||
US10/673,077 US20040209307A1 (en) | 2001-08-20 | 2003-09-26 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/714,078 US20040219509A1 (en) | 2001-08-20 | 2003-11-14 | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US10/714,078 | 2003-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004059293A2 WO2004059293A2 (en) | 2004-07-15 |
WO2004059293A3 true WO2004059293A3 (en) | 2005-03-31 |
Family
ID=32686403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041453 WO2004059293A2 (en) | 2002-12-24 | 2003-12-23 | Markers for differential diagnosis and methods of use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1587955A4 (en) |
JP (1) | JP2006526140A (en) |
AU (1) | AU2003302340B8 (en) |
CA (1) | CA2511501A1 (en) |
WO (1) | WO2004059293A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US8221995B2 (en) | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
US9494598B2 (en) | 2006-04-04 | 2016-11-15 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
MXPA03004105A (en) | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Making a prognosis in cases of cardiac disease using a combination of markers. |
EP1565570A4 (en) | 2002-11-12 | 2005-12-28 | Becton Dickinson Co | Diagnosis of sepsis or sirs using biomarker profiles |
MXPA05005072A (en) | 2002-11-12 | 2005-07-22 | Becton Dickinson Co | Diagnosis of sepsis or sirs using biomarker profiles. |
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
CN101426526B (en) * | 2004-04-26 | 2012-06-20 | 森托科尔公司 | Solution phase biopanning method using engineered decoy proteins |
US7659087B2 (en) | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
AU2005266921B2 (en) | 2004-07-23 | 2009-07-23 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
DE102004041659A1 (en) * | 2004-08-27 | 2006-03-02 | Institut Virion/Serion Gmbh | Test device for the in vitro diagnosis of multi-analyte tests and their use |
ITFI20040243A1 (en) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN |
JP4828550B2 (en) * | 2005-02-17 | 2011-11-30 | エフ.ホフマン−ラ ロシュ アーゲー | Use of the NT-proANP / NT-proBNP ratio to diagnose cardiac dysfunction |
JP2008538007A (en) | 2005-04-15 | 2008-10-02 | ベクトン,ディッキンソン アンド カンパニー | Diagnosis of sepsis |
EP1888765A4 (en) * | 2005-06-09 | 2008-11-05 | Biosite Inc | Methods and compositions for the diagnosis of venous thromboembolic disease |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
US20070003981A1 (en) * | 2005-06-29 | 2007-01-04 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
CA2614737A1 (en) * | 2005-07-08 | 2007-01-18 | Philadelphia Health & Education Corporation D/B/A Drexel University Coll Ege Of Medicine | Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2 |
EP1915465A2 (en) * | 2005-07-14 | 2008-04-30 | Inverness Medical Switzerland GmbH | Mitochondrial markers of ischemia |
DE102005034174A1 (en) * | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | CSF in vitro diagnostic procedure for dementia and neuroinflammatory diseases |
DE102005036094A1 (en) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro method for the diagnosis of neurodegenerative diseases |
JP2007082433A (en) * | 2005-09-20 | 2007-04-05 | Niigata Univ | Malignant brain tumor marker gene and use of the same |
US20080227713A1 (en) * | 2005-10-03 | 2008-09-18 | Protter Andrew A | Oxidized Human Bnp |
CA2633291A1 (en) * | 2005-12-15 | 2007-07-12 | Becton Dickinson And Company | Diagnosis of sepsis |
EP1845379A1 (en) * | 2006-04-13 | 2007-10-17 | F. Hoffmann-La Roche AG | Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath |
AU2007249620A1 (en) | 2006-05-09 | 2007-11-22 | Musc Foundation For Research Development | Detecting diastolic heart failure by protease and protease inhibitor plasma profiling |
DE102006023175A1 (en) | 2006-05-17 | 2007-11-22 | B.R.A.H.M.S Aktiengesellschaft | In vitro diagnostic and early diagnosis of neurodegenerative diseases |
DE102006027818A1 (en) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases |
DE102006034142A1 (en) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides |
EP1882947A1 (en) * | 2006-07-28 | 2008-01-30 | F. Hoffmann-La Roche AG | Means and methods for the differentation of cardiac and pulmonary causes of acute shortness of breath |
CA2660691C (en) * | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
WO2008021290A2 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
EP1909206A1 (en) * | 2006-09-11 | 2008-04-09 | Roche Diagnostics GmbH | Improvement of measuring range of a chromatographic rapid test |
ES2334155T3 (en) * | 2006-09-15 | 2010-03-05 | F. Hoffmann-La Roche Ag | BIOCHEMICAL MARKERS FOR ACUTE PULMONARY EMBOLISM. |
US8449864B2 (en) | 2006-10-20 | 2013-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Neurotensin as a marker and therapeutic target for sepsis |
DE102006053442A1 (en) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II |
WO2008061149A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
EP2095107B1 (en) | 2006-11-14 | 2014-07-02 | Alere San Diego, Inc. | Methods for risk assignment |
SE532103C2 (en) | 2006-12-12 | 2009-10-27 | Knut Johansen | Method for determining the health status of analytes in liquid samples |
DE102007022367A1 (en) * | 2007-05-07 | 2008-11-20 | B.R.A.H.M.S Ag | Method for the determination of amino-terminal pro-ANP in overweight patients |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
EP2020603A1 (en) * | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Method for risk stratification in stable coronary artery disease |
CN110346577A (en) | 2007-08-03 | 2019-10-18 | B.R.A.H.M.S 有限公司 | Application of the Procalcitonin (PCT) in the risk stratification and prognosis of patient for suffering from primary uninfection |
US20090075266A1 (en) * | 2007-09-14 | 2009-03-19 | Predictive Biosciences Corporation | Multiple analyte diagnostic readout |
US8431367B2 (en) | 2007-09-14 | 2013-04-30 | Predictive Biosciences Corporation | Detection of nucleic acids and proteins |
EP2031397A1 (en) | 2007-08-30 | 2009-03-04 | F. Hoffmann-La Roche AG | Surfactant proteins B and D in differentiating the causes of shortness of breath |
US7955822B2 (en) | 2007-09-14 | 2011-06-07 | Predictive Biosciences Corp. | Detection of nucleic acids and proteins |
US8852893B2 (en) | 2007-09-14 | 2014-10-07 | Physicians Choice Laboratory Services, Llc | Detection of nucleic acids and proteins |
JP5010034B2 (en) | 2007-12-28 | 2012-08-29 | エフ.ホフマン−ラ ロシュ アーゲー | Physiological status assessment |
CN102037355A (en) * | 2008-03-04 | 2011-04-27 | 里奇诊断学股份有限公司 | Diagnosing and monitoring depression disorders based on multiple biomarker panels |
US20110160070A1 (en) * | 2008-03-10 | 2011-06-30 | Lineagen, Inc. | Copd biomarker signatures |
CA2718273A1 (en) * | 2008-03-12 | 2009-09-17 | Ridge Diagnostics, Inc. | Inflammatory biomarkers for monitoring depression disorders |
US7776522B2 (en) | 2008-04-24 | 2010-08-17 | Becton, Dickinson And Company | Methods for diagnosing oncogenic human papillomavirus (HPV) |
EP2318844A1 (en) * | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
CA2733990C (en) | 2008-08-11 | 2018-12-11 | Banyan Biomarkers, Inc. | Biomarker detection process and assay of neurological condition |
JP2011530705A (en) * | 2008-08-13 | 2011-12-22 | エフ.ホフマン−ラ ロシュ アーゲー | D-dimer for pulmonary embolism, troponin, NT-proBNP |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
JP5219048B2 (en) * | 2008-09-17 | 2013-06-26 | 独立行政法人農業・食品産業技術総合研究機構 | Method for evaluating animal stress using anti-porcine interleukin-18 antibody |
JP5902479B2 (en) * | 2008-10-24 | 2016-04-13 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methods for prognosis and risk assessment in stroke patients by determining the level of marker peptides |
WO2010059709A2 (en) * | 2008-11-18 | 2010-05-27 | Ridge Diagnostics, Inc. | Metabolic syndrome and hpa axis biomarkers for major depressive disorder |
ES2684493T3 (en) | 2009-03-11 | 2018-10-03 | Promedior Inc. | An SAP polypeptide for use in the treatment of autoimmune disorders and graft disease against the host |
DK2405928T3 (en) | 2009-03-11 | 2017-01-30 | Promedior Inc | Treatment and diagnosis procedure for hypersensitive diseases |
WO2010132502A2 (en) | 2009-05-11 | 2010-11-18 | Cytotech Labs, Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
WO2011023813A1 (en) | 2009-08-28 | 2011-03-03 | Brahms Gmbh | Procalcitonin for the prognosis of adverse events |
US20130022982A1 (en) | 2009-09-14 | 2013-01-24 | Kevin Ka-Wang Wang | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
ES2592386T3 (en) | 2009-12-20 | 2016-11-29 | Astute Medical, Inc. | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
PT2666872T (en) * | 2010-02-05 | 2016-07-08 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2011110565A1 (en) * | 2010-03-08 | 2011-09-15 | B.R.A.H.M.S Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
DK2550365T3 (en) | 2010-03-22 | 2018-09-10 | Stemina Biomarker Discovery Inc | PREVENTION OF HUMAN DEVELOPMENTAL TOXICITY OF MEDICINAL PRODUCTS USING HUMAN STEM CELL-LIKE CELLS AND METABOLOMICS |
CA2797787C (en) | 2010-04-29 | 2019-07-09 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
EP2566971B1 (en) | 2010-05-06 | 2019-03-27 | Singulex, Inc. | Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis |
EP2598887B1 (en) * | 2010-07-28 | 2015-08-19 | Abbott GmbH & Co. KG | Method for detection of ischemic strokes |
WO2012065095A2 (en) * | 2010-11-11 | 2012-05-18 | Medical University Of South Carolina | Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling |
EP2492691A1 (en) | 2011-02-22 | 2012-08-29 | Institut de Recerca Hospital Universitari Vall d'Hebron | Method of predicting the evolution of a patient suffering of a neurovascular disease |
WO2012123299A1 (en) | 2011-03-11 | 2012-09-20 | Roche Diagnostics Gmbh | Asc as marker for chronic obstructive pulmonary disease (copd) |
AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
KR101894417B1 (en) | 2011-05-09 | 2018-09-03 | 세키스이 메디칼 가부시키가이샤 | Method for immunologically measuring soluble lr11 |
RU2469332C1 (en) * | 2011-10-12 | 2012-12-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации | Differential diagnostic technique for bronchial asthma |
ES2595028T3 (en) | 2011-10-17 | 2016-12-27 | F. Hoffmann-La Roche Ag | Troponin and BNP based diagnosis of patients at risk and cause of stroke |
EP2786154B1 (en) * | 2011-12-01 | 2017-11-01 | Roche Diagnostics GmbH | Nt-proanp and nt-probnp for the diagnosis of stroke |
ES2933570T3 (en) | 2011-12-08 | 2023-02-10 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of kidney injury and kidney failure |
EP2597465A1 (en) * | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | TnT and H-FABP for diagnosis of cardiac damage in infection |
WO2014072500A1 (en) | 2012-11-09 | 2014-05-15 | Roche Diagnostics Gmbh | Tnt based diagnosis of paroxysmal atrial fibrillation |
US9295393B2 (en) | 2012-11-09 | 2016-03-29 | Elwha Llc | Embolism deflector |
EP3734280B8 (en) | 2013-01-17 | 2022-08-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
JP2016507235A (en) * | 2013-02-01 | 2016-03-10 | ウエストバージニア ユニバーシティWest Virginia University | Biomarker algorithm and method for determining the time of onset of stroke symptoms |
KR101494882B1 (en) | 2013-02-21 | 2015-02-25 | 한국과학기술연구원 | A composition for diagnosing acute myocardial infarction, a kit for diagnosing acute myocardial infarction comprising the composition, and a method for diagnosing acute myocardial infarction |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
GB201309928D0 (en) * | 2013-06-04 | 2013-07-17 | Randox Lab Ltd | Method |
EP3757226A3 (en) | 2013-07-17 | 2021-05-05 | The Johns Hopkins University | A multi-protein biomarker assay for brain injury detection and outcome |
CA2922331A1 (en) * | 2013-08-30 | 2015-03-05 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
EP3730131A1 (en) | 2013-09-04 | 2020-10-28 | Berg LLC | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
FR3010187A1 (en) * | 2013-09-05 | 2015-03-06 | Ct Hospitalier Universitaire Rouen | USE OF UROTENSIN II AND / OR URP AS MARKERS FOR THE DIAGNOSIS OF POST HSA VASOSPASM |
WO2015042465A1 (en) * | 2013-09-20 | 2015-03-26 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain |
US9784749B2 (en) * | 2013-11-15 | 2017-10-10 | Otago Innovation Limited | Biomarker for cardiac disorders |
US9176113B1 (en) | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
EP3146077A4 (en) | 2014-05-22 | 2018-05-02 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
AU2015263998A1 (en) | 2014-05-22 | 2016-12-08 | Northwestern University | Gene expression profiles associated with sub-clinical kidney transplant rejection |
WO2015179777A2 (en) | 2014-05-22 | 2015-11-26 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
EP3502271A3 (en) * | 2014-10-22 | 2019-08-14 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Blood biomarkers for appendicitis and diagnostics methods using biomarkers |
US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
US10690681B2 (en) | 2015-03-06 | 2020-06-23 | Washington University | Methods to detect myocardial injury and uses thereof |
WO2017067821A1 (en) * | 2015-10-22 | 2017-04-27 | Universite Pierre Et Marie Curie (Paris 6) | A method for determining presence or risk of hemostasis disorder |
KR101801092B1 (en) | 2016-01-28 | 2017-11-28 | 순천향대학교 산학협력단 | Composition for Idiopathic pulmonary fibrosis prognosis and method of providing the information for the same |
AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
CN108728525B (en) * | 2017-04-19 | 2021-06-22 | 香港中文大学 | Circulating microRNA biomarker for subarachnoid hemorrhage and application thereof |
JP7109484B2 (en) * | 2017-06-13 | 2022-07-29 | エフ.ホフマン-ラ ロシュ アーゲー | Fatty acid binding protein 3 for assessment of atrial fibrillation (AF) |
WO2019018545A1 (en) | 2017-07-18 | 2019-01-24 | The Research Foundation For The State University Of New York | Biomarkers for intracranial aneurysm |
CN109975548B (en) * | 2018-03-08 | 2020-08-07 | 中山大学 | Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent |
US20210041468A1 (en) * | 2018-03-30 | 2021-02-11 | National Center Of Neurology And Psychiatry | Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method |
EP3553520A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Methods, uses and kits for monitoring or predicting response to periodontal disease treatment |
EP3553518A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Periodontitis diagnostic methods, uses and kits |
EP3553525A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Diagnostics of mild or advanced periodontitis |
EP3553524A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Periodontitis diagnostic methods, uses and kits |
JP7398226B2 (en) | 2019-09-03 | 2023-12-14 | 浜松ホトニクス株式会社 | Methods for assessing the risk of developing colorectal cancer |
JPWO2021199792A1 (en) * | 2020-04-02 | 2021-10-07 | ||
CN113791219B (en) * | 2020-07-24 | 2022-08-02 | 首都医科大学附属北京天坛医院 | Biomarker for acute ischemic stroke recurrence risk analysis and application thereof |
CN113252910B (en) * | 2021-06-29 | 2022-05-17 | 中国人民解放军军事科学院军事医学研究院 | Application of TIMP3 in anxiety and depression diagnosis |
CN115287346A (en) * | 2022-05-26 | 2022-11-04 | 中山大学深圳研究院 | Acute myocardial infarction early detection marker and detection kit |
CN116059328A (en) * | 2022-09-14 | 2023-05-05 | 深圳先进技术研究院 | Application of TIMP3 recombinant protein in preparation of preparation for inhibiting hypertensive renal clear cell carcinoma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599668A (en) * | 1994-09-22 | 1997-02-04 | Abbott Laboratories | Light scattering optical waveguide method for detecting specific binding events |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20030153014A1 (en) * | 1999-10-08 | 2003-08-14 | Li Shen | Compositions and methods for detecting protein modification and enzymatic activity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604105B1 (en) * | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
CA2263063C (en) * | 1999-02-26 | 2004-08-10 | Skye Pharmatech Incorporated | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein |
AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
AU2002305394A1 (en) * | 2001-05-04 | 2002-11-18 | Biosite, Inc. | Diagnostic markers of acute coronary syndromes and methods of use thereof |
-
2003
- 2003-12-23 CA CA002511501A patent/CA2511501A1/en not_active Abandoned
- 2003-12-23 JP JP2005510072A patent/JP2006526140A/en active Pending
- 2003-12-23 WO PCT/US2003/041453 patent/WO2004059293A2/en active Application Filing
- 2003-12-23 AU AU2003302340A patent/AU2003302340B8/en not_active Expired
- 2003-12-23 EP EP03810896A patent/EP1587955A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599668A (en) * | 1994-09-22 | 1997-02-04 | Abbott Laboratories | Light scattering optical waveguide method for detecting specific binding events |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
US20030153014A1 (en) * | 1999-10-08 | 2003-08-14 | Li Shen | Compositions and methods for detecting protein modification and enzymatic activity |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP1587955A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US8343728B2 (en) | 2006-04-04 | 2013-01-01 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US8535895B2 (en) | 2006-04-04 | 2013-09-17 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US9182405B2 (en) | 2006-04-04 | 2015-11-10 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US9494598B2 (en) | 2006-04-04 | 2016-11-15 | Singulex, Inc. | Highly sensitive system and method for analysis of troponin |
US8221995B2 (en) | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
Also Published As
Publication number | Publication date |
---|---|
EP1587955A4 (en) | 2007-03-14 |
JP2006526140A (en) | 2006-11-16 |
EP1587955A2 (en) | 2005-10-26 |
CA2511501A1 (en) | 2004-07-15 |
AU2003302340B8 (en) | 2008-09-11 |
AU2003302340A1 (en) | 2004-07-22 |
WO2004059293A2 (en) | 2004-07-15 |
AU2003302340B2 (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004059293A3 (en) | Markers for differential diagnosis and methods of use thereof | |
WO2002042775A3 (en) | Clinically intelligent diagnostic devices and methods | |
WO2005027733A3 (en) | Biological markers for diagnosing multiple sclerosis | |
WO2006089233A3 (en) | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia | |
WO2006071247A3 (en) | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots | |
WO2002089657A3 (en) | Diagnostic markers of acute coronary syndromes and methods of use thereof | |
WO2004048598A3 (en) | Molecular nephrotoxicology modeling | |
WO2003023573A3 (en) | Patient classification | |
WO2002095000A8 (en) | Molecular toxicology modeling | |
WO2004063753A3 (en) | A serum marker for measuring liver fibrosis | |
WO2006128042A3 (en) | Methods of identifying mutations in nucleic acid | |
WO2004007743A3 (en) | Use of cpg nucleic acids in prion-disease | |
WO2007132120A3 (en) | Procedure and methods for detecting alzheimer's disease | |
WO2004082617A3 (en) | Biological markers for diagnosing rheumatoid arthritis | |
FR2924118B1 (en) | INHIBITOR FRAGMENTS OF THE NEF PROTEIN OF HIV. | |
WO2006099543A3 (en) | Methods for assessing antibody-mediated cytotoxicity | |
BR0014150A (en) | Diagnostics and therapeutics for osteoporosis | |
WO2007061988A3 (en) | Methods for determining notch signaling and uses thereof | |
JP2007508527A5 (en) | ||
WO2006002930A3 (en) | FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS | |
WO2004063334A8 (en) | Molecular cardiotoxicology modeling | |
WO2004053459A3 (en) | Compounds and mehtods of use thereof for assaying lysophospholipase d activity | |
WO2003001182A3 (en) | Homocysteinylated transthyretin | |
WO2004110365A3 (en) | Liver related disease compositions and methods | |
WO2009089277A3 (en) | Rel inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2511501 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169348 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005510072 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3018/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003302340 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003810896 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A98399 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003810896 Country of ref document: EP |